S2 Episode 5: The Future of Asthma Care: Glas...

Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticl ...  Show more

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as Non-alcoholic fatty liver disease (NAFLD), is estimated to affect up to 1 in 5 people in the UK. Rates are increasing with rising levels of obesity. Although most cases of MASLD are linked to excess w ...  Show more

What if your fatigue, weight gain, hormone imbalances, and brain fog all traced back to a silent disease that affects 1 in 3 people—and you didn’t even know you had it? In today’s episode, I’m joined by Dr. Elizabeth Boham and Dr. Yousef Elyaman to talk about a condition that’s q ...  Show more

Interview with Fasiha Kanwal, MD, MSHS, author of GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Hosted by Eve Rittenberg, MD, and Grace Yuan Zhang, MD Related Content: GLP-1 Rece ...  Show more

Non-alcoholic fatty liver disease (NAFLD) presents as a disease spectrum. Fatty change is a common and frequently benign condition, present in 20-30% of the population and up to 90% of the morbidly obese. This Essential Knowledge Update (EKU2017.1) podcast explores the NICE guide ...  Show more